NeuroPace | MedPath

Rapport Therapeutics' RAP-219 Shows Promise in Phase 1 Trials for CNS Disorders

4 months ago

• Rapport Therapeutics' RAP-219 achieved target receptor occupancy within five days, supporting its potential for treating CNS disorders. • The Phase 1 trials demonstrated a favorable tolerability profile for RAP-219, with no serious adverse events reported in healthy volunteers. • RAP-219 selectively targets TARPγ8-associated AMPA receptors, potentially enhancing the therapeutic index for AMPA receptor modulation. • A Phase 2a trial of RAP-219 in focal epilepsy is ongoing, with topline data expected in mid-2025, according to Rapport Therapeutics.

NeuroPace Submits Landmark Three-Year Data for RNS System in Drug-Resistant Epilepsy Treatment

7 months ago

• NeuroPace has submitted three-year safety and effectiveness data from its largest prospective neuromodulation trial, involving over 300 patients with drug-resistant focal epilepsy, to the FDA. • The RNS System stands as the only neuromodulation device offering both stimulation delivery and patient response monitoring capabilities, marking a significant advancement in epilepsy treatment technology. • The study, conducted across more than 30 Level 4 Comprehensive Epilepsy Centers, will continue to track outcomes through a five-year follow-up period as part of the system's FDA approval requirements.

NeuroPace Submits Three-Year Data from RNS System Post-Approval Study to FDA

7 months ago

• NeuroPace has submitted three-year safety and effectiveness data from its Post-Approval Study (PAS) of the RNS System to the FDA. • The PAS is the largest prospective study in neuromodulation for drug-resistant focal epilepsy, involving over 300 patients. • The RNS System is the first brain-responsive platform delivering personalized, real-time treatment at the seizure source. • The study will continue to a five-year follow-up, supporting physicians in optimizing care for drug-resistant focal epilepsy patients.

NeuroPace Submits Three-Year Data from RNS System Post-Approval Study to FDA

7 months ago

• NeuroPace has submitted three-year safety and effectiveness data to the FDA from its Post-Approval Study (PAS) of the RNS System for drug-resistant focal epilepsy. • The RNS System PAS is the largest prospective post-approval study in neuromodulation, involving over 300 patients with drug-resistant focal epilepsy across multiple centers. • The study evaluates the RNS System's performance in adults with focal epilepsy, the most common form of drug-resistant epilepsy, with a five-year follow-up planned. • The RNS System is the only neuromodulation device that provides stimulation and monitors response, offering a personalized approach to optimize care for patients.

Rapport Therapeutics Gains Buy Recommendation Based on RAP Platform and RAP-219 Potential

7 months ago

• Rapport Therapeutics receives a Buy rating from JonesTrading, driven by its innovative RAP platform targeting central nervous system disorders. • RAP-219, Rapport's lead candidate, shows promise for treating epilepsy, pain, and bipolar disorder by targeting TARPγ8, with Phase II trials planned for 2025. • Integration of NeuroPace's RNS device could enhance clinical proof of concept for RAP-219, improving patient recruitment and trial outcomes. • Strategic focus on selective targeting aims to minimize side effects, potentially positioning RAP-219 as a best-in-class treatment.